PALVELLA THERAPEUTICS, INC. 10-K — AI Bull & Bear Analysis

The 10-K reveals a company at a critical binary inflection point. Palvella has successfully navigated the clinical validation of its QTORIN platform and secured the capital necessary to reach the regulatory finish line. However, the tension between management's optimistic timeline and the FDA's specific feedback regarding endpoints creates a high-variance outcome for investors. The success of the 505(b)(2) bridging strategy is now the primary catalyst. Ultimately, the investment thesis hinges on whether the FDA accepts the current data package for a rolling NDA submission in 2026. If accepted, Palvella transforms into a commercial-stage rare disease leader. If rejected, the company faces a race against time to fund additional trials while managing a high-interest royalty burden. The 2026 pre-NDA meeting will be the definitive signal for the company's near-term valuation.